A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
view all Clinical Trials
Overview
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy
Contact
For more information about this trial or to inquire about eligibility, call 215-707-5440 or email theresa.ropars@tuhs.temple.edu.